Literature DB >> 4027118

Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects.

S A Ward, G W Mihaly, G Edwards, S Looareesuwan, R E Phillips, P Chanthavanich, D A Warrell, M L Orme, A M Breckenridge.   

Abstract

We have investigated the pharmacokinetics of primaquine after acute and chronic administration of the drug to five healthy Thai volunteers. After acute dosage (15 mg p.o.) mean (+/- s.d.) peak plasma concentrations of 65.0 +/- 34.7 ng ml-1 were achieved within 2 +/- 1h. Thereafter plasma drug concentrations declined monoexponentially with a mean elimination half life of 4.4 +/- 1.4 h. The mean (+/- s.d.) oral clearance was 37.6 +/- 15.5 1 h-1. These values are in broad agreement with values obtained in healthy Caucasians after administration of an equivalent dose of primaquine. Repeated dosing with primaquine had no effect on the mean pharmacokinetic parameters calculated for this drug. In contrast, individual pharmacokinetic parameters for some subjects exhibited gross and unpredictable changes after chronic dosage. The carboxylic acid metabolite of primaquine accumulated in plasma after repeated dosing such that by day 14 of chronic dosing the mean AUC (0,24) for this metabolite was 74% greater than that obtained after acute administration of primaquine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027118      PMCID: PMC1463877          DOI: 10.1111/j.1365-2125.1985.tb02710.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography.

Authors:  S A Ward; G Edwards; M L Orme; A M Breckenridge
Journal:  J Chromatogr       Date:  1984-01-13

2.  Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat.

Authors:  D J Back; H S Purba; C Staiger; M L Orme; A M Breckenridge
Journal:  Biochem Pharmacol       Date:  1983-01-15       Impact factor: 5.858

3.  Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.

Authors:  G Acocella; R Mattiussi; G Segre
Journal:  Pharmacol Res Commun       Date:  1978-03

4.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Influence of long-term infusions on lidocaine kinetics.

Authors:  L A Bauer; T Brown; M Gibaldi; L Hudson; S Nelson; V Raisys; J P Shea
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

6.  Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite.

Authors:  G W Mihaly; S A Ward; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

7.  Effect of chloroquine and primaquine on antipyrine metabolism.

Authors:  D J Back; H S Purba; B K Park; S A Ward; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

8.  Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size.

Authors:  G W Mihaly; S A Ward; G Edwards; D D Nicholl; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

9.  Plasma kinetics and urinary excretion of primaquine in man.

Authors:  J Greaves; D A Evans; H M Gilles; K A Fletcher; D Bunnag; T Harinasuta
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

  9 in total
  21 in total

1.  Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.

Authors:  Chau Vuong; Lisa H Xie; Brittney M J Potter; Jing Zhang; Ping Zhang; Dehui Duan; Christina K Nolan; Richard J Sciotti; Victor E Zottig; N P Dhammika Nanayakkara; Babu L Tekwani; Larry A Walker; Philip L Smith; Robert M Paris; Lisa T Read; Qigui Li; Brandon S Pybus; Jason C Sousa; Gregory A Reichard; Bryan Smith; Sean R Marcsisin
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Lymphocyte proliferative response and subset profiles during extended periods of chloroquine or primaquine prophylaxis.

Authors:  D J Fryauff; A L Richards; J K Baird; T L Richie; E Mouzin; E Tjitra; M A Sutamihardja; S Ratiwayanto; H Hadiputranto; R P Larasati; N Pudjoprawoto; B Subianto; S L Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

3.  Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to Plasmodium vivax in the Brazilian Amazon Basin.

Authors:  José Luiz Vieira; Michelle E S Ferreira; Michelle V D Ferreira; Margarete M Gomes
Journal:  Am J Trop Med Hyg       Date:  2017-04-05       Impact factor: 2.345

Review 4.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

6.  Inhibition of cardiac Na+ current by primaquine.

Authors:  Gerardo Orta-Salazar; Ron A Bouchard; Fernando Morales-Salgado; Eduardo M Salinas-Stefanon
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

7.  The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration.

Authors:  H Yoshimura; Y S Endoh; Y Ishihara; S Nakamura; Y Inoue
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

8.  Pharmacokinetics of primaquine in patients with P. vivax malaria.

Authors:  S C Bhatia; Y S Saraph; S N Revankar; K J Doshi; E D Bharucha; N D Desai; A B Vaidya; D Subrahmanyam; K C Gupta; R S Satoskar
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Interactions among primaquine, malaria infection and other antimalarials in Thai subjects.

Authors:  G Edwards; C S McGrath; S A Ward; W Supanaranond; S Pukrittayakamee; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

10.  Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria.

Authors:  Brioni R Moore; Sam Salman; John Benjamin; Madhu Page-Sharp; Leanne J Robinson; Elizabeth Waita; Kevin T Batty; Peter Siba; Ivo Mueller; Timothy M E Davis; Inoni Betuela
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.